ArticleFederal practitioner : for the health care professionals of the VA, DoD, and PHS2026
Cannabis Use by Veterans and Potential Interactions With Antineoplastic Agents: Analysis and Literature Review.
Article in Federal practitioner : for the health care professionals of the VA, DoD, and PHS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Extensive research exists investigating medicinal uses of cannabis products in patients with malignancies, though it is largely unknown how cannabis use may affect the efficacy of antineoplastics. Like many antineoplastic agents, cannabis is metabolized by cytochrome P450, leading to potential interactions. This observational study sought to identify the prevalence of cannabis use in patients with a malignancy at the Veterans Affairs Memphis Healthcare System and analyze the potential for interactions between various products and the antineoplastic agents the patients received. Methods: A retrospective review of electronic health records was completed for patients who used cannabis products during treatment and accepted the invitation to complete a survey during January 2024. Prescribed antineoplastic medications for each patient were recorded, and data were compiled and analyzed for potential interactions. Results: A total of 132 patients agreed to participate in the survey, and 50 (38%) acknowledged use of cannabis products within the previous 90 days. Forty-five patients (90%) who used cannabis within 90 days were male, and 29 patients (58%) were aged 60 to 65 years. Thirty-five patients (70%) predominantly inhaled cannabis. Twenty-one patients (42%) had chemotherapy, the most common treatment, 19 patients (38%) had immunotherapy, 12 patients (24%) used targeted therapy, and 10 patients (20%) used endocrine therapy. Conclusions: This analysis found a notable prevalence of patients with cancer concurrently using cannabis while being prescribed an antineoplastic. The results of this study suggest a potential decrease in the efficacy of immunotherapy and endocrine therapy and an increase in toxicity with chemotherapy and targeted agents when used alongside cannabis products.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.